STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
38.28 USD +1.54% Intraday chart for STAAR Surgical Company -1.80% +22.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
STAAR Surgical Company Announces Board Changes CI
North American Morning Briefing : Inflation Data -2- DJ
Stifel Upgrades STAAR Surgical to Buy From Hold, Raises Price Target to $50 From $30 MT
Mizuho Securities Adjusts Price Target on STAAR Surgical to $45 From $50, Keeps Buy Rating MT
Piper Sandler Cuts STAAR Surgical Price Target to $33 From $40, Maintains Neutral Rating MT
STAAR Surgical Q4 Earnings, Revenue Rise MT
Transcript : STAAR Surgical Company, Q4 2023 Earnings Call, Feb 26, 2024
STAAR Surgical Company Affirms Earnings Guidance for the Fiscal Year 2024 CI
STAAR Surgical Company Reports Earnings Results for the Full Year Ended December 29, 2023 CI
STAAR Surgical Company Reports Earnings Results for the Fourth Quarter Ended December 29, 2023 CI
Earnings Flash (STAA) STAAR SURGICAL COMPANY Posts Q4 Revenue $76.3M, vs. Street Est of $75.8M MT
North American Morning Briefing : Traders Await -2- DJ
STAAR Surgical Announces Marketing Deal for EVO ICL With SharpeVision MT
STAAR Surgical Company Announces Strategic Agreement in U.S. with SharpeVision CI
Broadwood Partners Engages in Discussions with STAAR Surgical CI
Staar Surgical Company Provides Sales Guidance for the Fiscal 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Needham Downgrades STAAR Surgical to Hold From Buy MT
STAAR Surgical Company Announces Board Changes CI
Morgan Stanley Initiates STAAR Surgical at Equal-Weight Rating With $35 Price Target MT
STAAR Surgical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Needham Adjusts Price Target on STAAR Surgical Company to $49 From $52, Keeps Buy Rating MT
STAAR Surgical Q3 Earnings Down, Revenue Up MT
Transcript : STAAR Surgical Company, Q3 2023 Earnings Call, Nov 01, 2023
Earnings Flash (STAA) STAAR SURGICAL COMPANY Posts Q3 Revenue $80.3M, vs. Street Est of $80.4M MT
Chart STAAR Surgical Company
More charts
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
38.28 USD
Average target price
43.72 USD
Spread / Average Target
+14.22%
Consensus